A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2400 participants.

Also called NCT02057302

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,400 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02057302
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02057302. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
Condition
Dyslipidemia
Intervention (Drug)
Xuezhikang capsule
Lead sponsor
China Academy of Chinese Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct02057302
Content hash
7d700af19f7f3894c5686805f317d8c83c537ad6bf9402c4b18e378bed0ea9be